The performance of companies tied to Viagra's legacy presents a complex investment picture . While the initial boom generated substantial returns , generic copies have significantly impacted sales . Investing in related pharmaceutical businesses now requires a thorough assessment of proprietary safeguards, evolving patient changes, and the prospect